Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

ACEP Clinical Policy Committee’s Patient Management Recommendations

By ACEP Now | on September 1, 2009 | 0 Comment
From the College
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version
  • Level A recommendations. Do not utilize cardiac serum marker tests to exclude non-AMI acute coronary syndromes (i.e., unstable angina).
  • Level B recommendations. Utilize any of the following cardiac serum marker tests to exclude non–ST-segment elevation AMI as denied by the World Health Organization (WHO) or modified WHO criteria.*
    1. A single negative CK-MB mass, Troponin I, or Troponin T measured 8 to 12† hours after symptom onset.‡
    2. A negative myoglobin in conjunction with a negative CK-MB mass, or negative Troponin§ when measured at baseline and 90 minutes in patients presenting less than 8 hours after symptom onset.‡
    3. A negative 2-hour delta CK-MB mass** in conjunction with a negative 2-hour delta Troponin§,** in patients presenting less than 8 hours after symptom onset.‡
  • Level C recommendations. None specified.

* There is insufficient evidence at this time to make any recommendations in regard to utilization of cardiac serum markers to exclude non–ST-segment elevation AMI using current Joint European Society of Cardiology(ESC)/ACC criteria for AMI.

You Might Also Like
  • World Health Organization Recommendations for Community Management of Opioid Overdose Reviewed by ACEP Clinical Policies Committee
  • ACEP Clinical Policy Review: Evaluation and Management of Adult Patients in the ED with Asymptomatic Elevated BP
  • ACEP Clinical Policy: Critical Issues in the Management Of Adult Patients With Community-Acquired Pneumonia
Explore This Issue
ACEP News: Vol 28 – No 09 – September 2009

† The exact timing of serum marker measurement as it relates to time of symptom onset should take into account the sensitivity, precision, and institutional norms of the assay being utilized, as well as the release kinetics of the marker being measured.

‡ If time of symptom onset is unknown, unreliable, or more consistent with preinfarctional angina, then time of symptom onset should be referenced to the time of ED presentation.

§ Only Troponin I has been investigated in the serial 90 minute multimarker protocol and the 2-hour delta protocol.

** The appropriate delta values for exclusion of AMI should take into account the sensitivity and precision of the assay used and confirmed by in-house studies. It is also important that delta serum marker levels are measured on the same instrument due to subtle variations in calibration among individual instruments of the same model.

Current Issue

ACEP Now May 03

Read More

About the Author

ACEP Now

View this author's posts »

No Responses to “ACEP Clinical Policy Committee’s Patient Management Recommendations”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603